Primary Prevention of Sudden Arrhythmic Death in Dilated Cardiomyopathy: Current Guidelines and Risk Stratification

JACC: Heart Failure

Volumn 5, Issue 1, 2017, Pages 39-43

  Arbustini, Eloisa ^a   Disertori, Marcello ^b   Narula, Jagat ^c  

^a FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

^b SANTA CHIARA HOSPITAL   (Italy)

^c MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

genetics; implantable cardioverter defibrillator; late gadolinium enhancement; sudden cardiac death

Indexed keywords

AMYLOIDOSIS; ATRIOVENTRICULAR NODAL REENTRY TACHYCARDIA; CONGESTIVE CARDIOMYOPATHY; CORRELATION ANALYSIS; EDITORIAL; GENE MUTATION; GENETIC ANALYSIS; HEART ARRHYTHMIA; HEART LEFT VENTRICLE EJECTION FRACTION; HEART VENTRICLE TACHYCARDIA; HUMAN; IMAGE ANALYSIS; IMAGE ENHANCEMENT; IMPLANTABLE CARDIOVERTER DEFIBRILLATOR; PRACTICE GUIDELINE; PREVENTIVE MEDICINE; PRIMARY PREVENTION; PRIORITY JOURNAL; SUDDEN CARDIAC DEATH; HEART FAILURE; RISK ASSESSMENT; RISK FACTOR;

CARDIOMYOPATHY, DILATED; DEATH, SUDDEN, CARDIAC; DEFIBRILLATORS, IMPLANTABLE; HEART FAILURE; HUMANS; PRIMARY PREVENTION; RISK ASSESSMENT; RISK FACTORS;

EID: 85007524726     PISSN: 22131779     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jchf.2016.11.009     Document Type: Editorial

References (13)

1. 1 Priori, S.G., Blomstrom-Lundqvist, C., Mazzanti, A., et al. 2015 ESC guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death. Eur Heart J 36 (2015), 2793–2867.
2. 2 Køber, L., Thune, J.J., Nielsen, J.C., et al. Defibrillator implantation in patients with nonischemic systolic heart failure. N Engl J Med 375 (2016), 1221–1230.
3. 3 Disertori, M., Rigoni, M., Pace, N., et al. Myocardial fibrosis assessment by LGE is a powerful predictor of ventricular tachyarrhythmias in ischemic and nonischemic LV dysfunction. A meta-analysis. J Am Coll Cardiol Img 9 (2016), 1046–1055.
4. 4 Di Marco, A., Anguera, I., Schmitt, M., et al. Late gadolinium enhancement and the risk for ventricular arrhythmias or sudden death in dilated cardiomyopathy: systematic review and meta-analysis. J Am Coll Cardiol HF 5 (2017), 28–38.
5. 5 Gulati, A., Jabbour, A., Ismail, T.F., et al. Association of fibrosis with mortality and sudden cardiac death in patients with nonischemic dilated cardiomyopathy. JAMA 309 (2013), 896–908.
6. 6 Kadish, A.H., Bello, D., Finn, J.P., et al. Rationale and design for the Defibrillators to Reduce Risk by Magnetic Resonance Imaging Evaluation (DETERMINE) trial. J Cardiovasc Electrophysiol 20 (2009), 982–987.
7. 7 Disertori, M., Quintarelli, S., Mazzola, S., Favalli, V., Narula, N., Arbustini, E., The need to modify patient selection to improve the benefits of implantable cardioverter-defibrillator for primary prevention of sudden death in non-ischaemic dilated cardiomyopathy. Europace 15 (2013), 1693–1701.
8. 8 Arbustini, E., Narula, N., Tavazzi, L., et al. The MOGE(S) classification of cardiomyopathy for clinicians. J Am Coll Cardiol 64 (2014), 304–318.
9. 9 Pinto, Y.M., Elliott, P.M., Arbustini, E., et al. Proposal for a revised definition of dilated cardiomyopathy, hypokinetic non-dilated cardiomyopathy, and its implications for clinical practice: a position statement of the ESC working group on myocardial and pericardial diseases. Eur Heart J 37 (2016), 1850–1858.
10. 10 van Rijsingen, I.A., Arbustini, E., Elliott, P.M., et al. Risk factors for malignant ventricular arrhythmias in lamin A/C mutation carriers: a European cohort study. J Am Coll Cardiol 59 (2012), 493–500.
11. 11 Disertori, M., Gulizia, M.M., Casolo, G., et al. Improving the appropriateness of sudden arrhythmic death primary prevention by implantable cardioverter-defibrillator therapy in patients with low left ventricular ejection fraction. Point of view. J Cardiovasc Med 17 (2016), 245–255.
12. 12 Epstein, A.E., DiMarco, J.P., Ellenbogen, K.A., et al. 2012 ACCF/AHA/HRS focused update incorporated into the ACCF/AHA/HRS 2008 guidelines for device-based therapy of cardiac rhythm abnormalities: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol 61 (2013), e6–e75.
13. 13 Corrado, D., Wichter, T., Link, M.S., et al. Treatment of arrhythmogenic right ventricular cardiomyopathy/dysplasia: an international task force consensus statement. Eur Heart J 36 (2015), 3227–3237.